Compare Regions Financial Corporation Common Stock (RF) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regions Financial Corporation Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Regions Financial Corporation Common Stock trades at $26.93 (market cap $23.01B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Regions Financial Corporation Common Stock is far larger — about 4.7× Travere Therapeutics Inc. Common Stock's market cap, and Regions Financial Corporation Common Stock pays a 4.05% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regions Financial Corporation Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RF | TVTX | |
|---|---|---|
Market Cap | $23.01B | $4.88B |
Volume | 10,095,088 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $32.40 | $67.52 |
52-Week Low | $23.35 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.75B | $5.01B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regions Financial (RF) trades at $27.01, down 1.32% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.98, net income margin of 29.3%, and consistent earnings beats in recent quarters. Recent news highlights dividend declarations and upcoming Q3 earnings, while the company plans significant branch expansion.
The outlook is cautiously optimistic with a $32.78 consensus price target suggesting 21% upside. Key risks include elevated expenses and weaker capital markets revenue. Analyst sentiment is mixed with 40% buy ratings, but institutional interest remains strong with Bank of America's recent $219 million investment.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regions Financial Corporation Common Stock
Regions Financial is a financial holding company that operates through Regions Bank. It provides consumer, commercial, mortgage, wealth-management, and investment services across the South, Midwest, and Texas.
Read more on RF →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
